Jade Biosciences, Inc. (JBIO)

NASDAQ: JBIO · Real-Time Price · USD
7.32
-0.17 (-2.27%)
At close: May 22, 2025, 4:00 PM
7.27
-0.05 (-0.68%)
After-hours: May 22, 2025, 7:18 PM EDT
-2.27%
Market Cap 229.97M
Revenue (ttm) n/a
Net Income (ttm) -93.96M
Shares Out 31.42M
EPS (ttm) -18.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 226,025
Open 7.59
Previous Close 7.49
Day's Range 6.98 - 7.62
52-Week Range 1.25 - 25.29
Beta n/a
Analysts Buy
Price Target 17.00 (+132.24%)
Earnings Date May 14, 2025

About JBIO

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company was incorporated in 2024 and is headquartered in Waltham, Massachusetts. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2024
Employees 30
Stock Exchange NASDAQ
Ticker Symbol JBIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for JBIO stock is "Buy" and the 12-month stock price forecast is $17.0.

Price Target
$17.0
(132.24% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Completed reverse merger and commenced trading on Nasdaq as JBIO Closed financing, raising approximately $300 million to date, providing cash runway through 2027 Lead candidate JADE101 expected to ent...

8 days ago - GlobeNewsWire

Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference

SAN FRANCISCO and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies f...

9 days ago - GlobeNewsWire